Werewolf Therapeutics (HOWL) Non-Current Debt (2023 - 2025)
Werewolf Therapeutics (HOWL) posted quarterly Non-Current Debt of $21.7 million for Q3 2025, down 15.46% year-over-year from $25.6 million in Q3 2024, and down 12.34% on a QoQ basis from $24.7 million in Q2 2025.
Werewolf Therapeutics (HOWL) Non-Current Debt (2023 - 2025) Analysis & Trends
Werewolf Therapeutics has reported Non-Current Debt for 3 years, with the latest figure at $21.7 million in Q3 2025.
- Non-Current Debt for Q3 2025 came in at $21.7 million, down 15.46% year-over-year; the trailing twelve-month figure through Sep 2025 was $21.7 million (down 15.46% YoY), and the FY2024 annual result was $26.1 million, down 20.09% from the prior year.
- Non-Current Debt fell to $21.7 million in Q3 2025, from $24.7 million in the prior quarter.
- Over five years, Non-Current Debt peaked at $39.1 million in Q2 2023 and troughed at $21.7 million in Q3 2025.
- A 3-year average of $29.6 million and a median of $26.6 million in 2025 frame the typical range for Non-Current Debt.
- The widest annual swing landed in 2024, when Non-Current Debt slumped 35.71%; it then retreated 1.82% in 2025.
- A 3-year view of Non-Current Debt shows it stood at $32.7 million in 2023, then fell by 20.09% to $26.1 million in 2024, then slipped by 17.01% to $21.7 million in 2025.
- Per Business Quant data, the three most recent Non-Current Debt figures were $21.7 million in Q3 2025, $24.7 million in Q2 2025, and $26.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.49 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.24 Bn | 78.25 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.08 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.83 Bn | 53.69 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 882.16 Mn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 360.97 Mn |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.44 Bn | - | 8.96 Bn |
| 10 | Werewolf Therapeutics | 43.97 Mn | 43.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 21.66 Mn |
| Jun 30, 2025 | 24.71 Mn |
| Mar 31, 2025 | 26.59 Mn |
| Dec 31, 2024 | 26.10 Mn |
| Sep 30, 2024 | 25.62 Mn |
| Jun 30, 2024 | 25.16 Mn |
| Mar 31, 2024 | 27.75 Mn |
| Dec 31, 2023 | 32.66 Mn |
| Sep 30, 2023 | 37.56 Mn |
| Jun 30, 2023 | 39.14 Mn |
| Mar 31, 2023 | 39.06 Mn |